RCMNY
VIRX

Rubric Capital Management (New York)’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Rubric Capital Management (New York)’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,487,385
Closed -$2.36M – 76
2023
Q1 		$2.36M Buy
1,487,385
+156,402
+12% +$284K 0.06% 67
2022
Q4 		$1.94M Buy
1,330,983
+336,182
+34% +$982K 0.08% 85
2022
Q3 		$4.25M Buy
+994,801
New +$4.21M 0.21% 66

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Rubric Capital Management (New York)'s VIRX Position: Q2 2023 in Review

Rubric Capital Management (New York) sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2023, closing a stake of 1,487,385 shares — an estimated $2.36M sold.

Rubric Capital Management (New York) first reported a position in VIRX in Q3 2022 and held it in 3 quarters. The position peaked at $4.25M in Q3 2022. 41 funds tracked by Wall St. Rank hold VIRX as of Q2 2023.

  • Rubric Capital Management (New York) reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Rubric Capital Management (New York) sold 1,487,385 Viracta Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $2.36M.
  • Rubric Capital Management (New York) first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2022 and held it in 3 quarters.
  • Rubric Capital Management (New York)'s Viracta Therapeutics, Inc. Common Stock position peaked at $4.25M in Q3 2022.
  • 41 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Rubric Capital Management (New York)'s 13F filing for Q2 2023, filed 11 Aug 2023.